Home | Back to newsletter main page

Bookmark and Share
Case Comprehensive Cancer Center Newsletter

November 14, 2011

CASE CCC IN THE NEWS

Why Men and Women React Differently to Cancer Gene
Bioidentical Hormone Health - Nov 14, 2011
Interestingly, Dr. Charis Eng, one of the lead researchers, has also made a link with why we are encouraged to drink red wine as a healthy daily preventive ...

Champion of Integrative Oncology Brings International Conference
Plain Dealer - Nov 9, 2011
... therapies with more standard approaches, says Dr. Stanton Gerson, director of the UH Seidman Cancer Center and of the Case Comprehensive Cancer Center. ...

Cleveland Clinic, UH Testing Therapies on Deadly Brain Tumors
Plain Dealer - Nov 7, 2011
Dr. Andrew Sloan, director of the Brain Tumor and Neuro-Oncology Center at University Hospitals Case Medical Center, is overseeing three separate clinical ..."We've been slowly chipping away at glioblastomas over the last couple decades," said Dr. Gene Barnett, director of the Clinic's Burkhardt Brain Tumor ... On Sept. 7, neurosurgeon Dr. Michael Vogelbaum biopsied a small part of the tumor, then injected the retrovirus right onto the active tumor cells...

Cancer Vaccines That Could Save Lives
WZVN-TV - Nov 6, 2011
"Basically, your immune cells will go looking for prostate cancer cells," says Dr. Jorge Garcia, an oncologist with the Cleveland Clinic... "It's like weeds in a garden," says Vincent K. Tuohy, PhD. "You just can't get rid of every weed, and I thought it would be easier to get them before they take root."...


MARK YOUR CALENDARS

Cancer Center Seminar Series: Novel NFκB and STAT Signaling Pathways Present Novel Targets for Drug Development in Cancer
Stark

Friday, November 18
12-1 pm
Frohring Auditorium - BRB 105

Please join us Friday, November 18 at the next Cancer Center Seminar Series featuring George R. Stark, PhD, Staff and Distinguished Scientist in the Department of Molecular Genetics at the Cleveland Clinic Lerner Research Institute and Professor Emeritus in the Department of Genetics at Case Western Reserve University. In his presentation, Novel NFκB and STAT Signaling Pathways Present Novel Targets for Drug Development in Cancer, Dr. Stark will summarize recent progress and future plans on three topics:

  • Proteins induced in response to the unphosphorylated form of the transcription factor STAT1 mediate resistance to DNA damage in many different cancers and also participate in the stepwise conversion of human mammary epithelial cells to tumors.
  • The protein tyrosine kinase FER connects growth factor receptors to activation of the survival factor NFκB through a novel pathway involving tyrosine rather than serine phosphorylation. This pathway contributes to resistance to receptor tyrosine kinase inhibitors such as imatinib and erlotinib in gastrointestinal stromal tumors and non-small cell lung cancer, suggesting that NFκB inhibitors such as quinacrine may be therapeutically useful in combination with receptor tyrosine kinase inhibitors.
  • Methylation of specific lysine residues of the pro-oncogenic transcription factors NFκB and STAT3 are important for their functions and thus present attractive targets for drug development. There is much recent information concerning the sites of methylation, the enzymes that carry out the reactions, and the functional consequences of methylation.

This seminar is hosted by the Cancer Cell Signaling Program, but all are encouraged to attend. CME credit is available.

Office of Cancer Centers Learning Series Webinar: Opportunity for CTSU Support for Collaborative Multi-Center Phase 2 Trials Led by NCI-Designated Cancer Centers and SPOREs

Please plan on participating in the next Office of Cancer Centers Learning Series Webinar on Monday, December 5 from 2-3:30 pm. The presentation will describe an opportunity for Cooperative Group, NCI Designated Cancer Center, and Specialized Programs of Research Excellence (SPORE) investigators to develop clinical trial collaborations through discussions in NCI's Scientific Steering Committees. For clinical trial collaborations requiring multi-center coordinating support that is not otherwise available through existing networks, NCI will prioritize requests for in-kind coordination support through its Cancer Trials Support Unit (CTSU). Featured speaker Raymond A. Petryshyn, PhD, Program Director of the Coordinating Center for Clinical Trials, will discuss the type of support available, eligibility criteria and the evaluation process for CTSU applications.


FUNDING OPPORTUNITIES

Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant

The AACR Pathway to Leadership Grant is designed to build future leaders in the pancreatic cancer research community by supporting a highly promising early-career scientist in his/her postdoctoral or clinical research fellowship through the transition to an independent researcher. Applicants must have started a postdoctoral or clinical research fellowship on or after July 2, 2007 (i.e., must be in the first five years of a fellowship at the start of the grant term).

Extended Deadline: November 29

Robert Wood Johnson Foundation Clinical Scholars Program

The Robert Wood Johnson Foundation and the U.S. Department of Veterans Affairs collaborate to foster the development of physicians who will lead the transformation of Americans' health and health care through the Robert Wood Johnson Foundation Clinical Scholars program. These future leaders will conduct innovative research and work with communities, organizations, practitioners and policy-makers to address issues essential to the health and well-being of all Americans.

Deadline: February 29, 2012


ANNOUNCEMENTS

Vogelbaum and Peereboom Elected to Society for Neuro-Oncology Board of Directors

The following Cancer Center members were recently elected to the Society for Neuro-Oncology Board of Directors: Dr. Michael Vogelbaum, Vice President, and Dr. David Peereboom, Medical Oncology Representative. The Society for Neuro-Oncology is the largest international scientific and professional multidisciplinary society focused on the science and treatment of central nervous system tumors.

NCI Releases Revised Best Practices for Biospecimen Resources

The NCI has announced the release of revised Best Practices for Biospecimen Resources. Originally released in 2007, this document identifies guiding principles defining state-of-the-science practices for biospecimen resources, promoting biospecimen and data quality, and supporting adherence to ethical and legal principles. This revised version incorporates more current and detailed recommendations, and responds to comments received from community stakeholders.

Major revisions include:

  • An interactive online format that allows greater flexibility and access to the information.
  • New sections on conflicts of interest and the management and operation of biospecimen resources.
  • Expanded recommendations related to custodianship and informed consent.
  • Harmonization with current Federal guidance documents and international biospecimen organizations.
  • Updated references throughout.

Like the 2007 release, this version of the NCI Best Practices underwent scrutiny by experts within NCI and throughout the NIH. A draft version of the revised document was posted online for public comment and all the input received was considered in the final version of the document.

Friends of Cancer Research, with the Support of Over 25 Leading Advocacy Organizations, Releases Report Identifying Comparative Effectiveness Research (CER) Priority Studies in Cancer

Last week, Friends of Cancer Research released a new report, Expanding Comparative Effectiveness Research: Priority Areas in Oncology. The report is the outgrowth of the June 2011 Friends of Cancer Research conference that brought together key stakeholders from the entire cancer community. Over 40 initial topics were submitted for review and public input.

The report describes specific areas of CER that could begin to improve the field of oncology. It contains 13 potential comparative effectiveness research studies in oncology that were identified by leaders of the cancer community and the Friends Comparative Effectiveness Research Advisory Committee, that could begin to be addressed by public and private-sector funders of research. These entities include the publicly funded Patient-Centered Outcomes Research Institute, other government agencies, academic research institutions and the private sector.

EVENTS

calendar

**All events are open to anyone interested in attending

November 14

Skeletal Research Center
Diego Correa, MD, PhD
Senior Research Associate, Skeletal Research Center, Biology
CWRU
Topic: BM-MSC/Pericytes: Gatekeepers Controlling Skeletal Metastasis
4 pm Millis 123


November 15

Hematology/Oncology Special Research Conference
Robert Van Buren Emmons, MD
Associate Professor, Medicine, BMT Program
Temple University
Topic: Stem Cell Transplant 2011 and the Way Forward
8 am Wearn 137

Cancer Biology Special Seminar
Steven Lipkin, MD, PhD
Associate Professor, Medicine and Genetic Medicine
Cornell University
Topic: The Chemokine 25 and Chemokine Receptor 9 Axis Suppresses Colon Cancer Invasion and Metastasis
11 am NC1-202 Cleveland Clinic

Immunology Seminar Series
Pamela Wearsch, PhD
Assistant Professor, Pathology
CWRU
Topic: Optimization of the MHC Class I Peptide Repertoire
12 pm WRB 1-413

Pharmacology Seminar
Steffi Oesterreich, PhD
Associate Professor, Pharmacology and Chemical Biology
University of Pittsburgh
Topic: Endocrine Resistance in Breast Cancer- Genetics or Epigenetics
12 pm Webster Conference Room, SOM W331


November 16

Hematology and Oncology Division Research Conference canceled

Immunology Visiting Professor Seminar Series
Laurence Morel, PhD
Director, Div. of Experimental Pathology
University of Florida
Topic: Dissection of the Murine Sle1 Lupus Susceptibility Locus
12 pm NC1-202 Cleveland Clinic


November 17

Molecular and Microbiology Seminar
Amanda Tomalka
Rietsch Lab, Molecular and Microbiology
CWRU
Topic: Export Signals of the P. Aeruginosa Type III Secretion Translocator PopD
AND
Arne Rietsch, PhD
Assistant Professor, Molecular and Microbiology
CWRU
Topic: Functional Interactions Among Translocator Proteins in the P. Aeruginosa Type III Secretion System
1 pm SOM W203


November 18

Hematology/Oncology Fellows Conference canceled

Taussig Cancer Institute Grand Rounds
Brandon Hayes-Lattin, MD
Medical Director, Adolescent and Young Adult Oncology Program
Oregon Health and Science University Knight Cancer Institute
Topic: What's Different About Adolescents and Young Adults (AYA) With Cancer?
8 am R3/002-003 Cleveland Clinic

Cancer Center Seminar Series
George Stark, PhD
Staff and Distinguished Scientist, Molecular Genetics, Lerner Research Institute
Professor Emeritus, Genetics
CWRU
Topic: Novel NFκB and STAT Signaling Pathways Present Novel Targets for Drug Development in Cancer
12 pm BRB 105

Cancer Center Research in Progress Seminar
Topic: TBD
4 pm WRB 3-136

 

 

Case CCC Calendar

LRI Calendar



PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES

NCI Provocative Questions Project
Deadline: November 14

Rita Allen Foundation Scholars Program
Internal Deadline: November 14

AACR–Conquer Cancer Foundation of ASCO Young Investigator Translational Cancer Research Award
Deadline: November 15

Cellular Molecular Imaging of Cancer Pilot Funding: Cancer Microenvironment
Deadline Extended: November 22

Robert Wood Johnson Foundation Community Health Leaders
Deadline: November 28

SU2C-PCF Prostate Dream Team Translational Cancer Research Grant
LOI Deadline: November 28

Burroughs Wellcome Fund Collaborative Research Travel Grants
Deadline: December 1

CTSC Core Utilization pilot program
Deadline: December 1

Kimmel Scholar Award
Deadline: December 1

Kimmel Translational Science Award
Deadline: December 1

American Medical Association Seed Grant Research Program
Deadline: December 5

2012 NIH Director's Transformative Research Awards
LOI Deadline: December 12
Application Deadline: January 12, 2012

L'Oréal USA Fellowships For Women In Science
Deadline: December 15

Lymphatic Research Foundation (LRF) Postdoctoral Fellowship Program
Deadline: January 10, 2012

HHMI Medical Research Fellows Program
Deadline: January 11, 2012

2012 CTSC Annual Pilot Grant Funding
Mandatory LOI Deadline: January 15

Oncology Nursing Society Foundation Connie Henke Yarbro Excellence in Cancer Nursing Mentorship Award
Deadline: January 15, 2012

Robert Wood Johnson Foundation Executive Nurse Fellows
Deadline: January 18, 2012

Innovations for Health: Solutions that Cross Borders
Deadline: February 13, 2012

Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)
Deadline: Open

AACR Scholar-in-Training Awards - Other Conferences and Meetings
Deadline: Open

Case CCC Protocol Specific Research Support (PSRS)
Deadline: Open

International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships
Application Deadline: Open

International Waldenstrom's Macroglobulinemia Foundation (IWMF) Research Grant Program
Application Deadline: Open

NCI Short-Term Scientist Exchange Program
Application Deadline: Open


NIH BULLETIN – Notices and Funding Opportunities

NIH Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (R01) (PAR-12-010)

NIH Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U01) (PAR-12-011)

Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216-844-8317 phone
216-844-7832 fax
gillian.irwin@case.edu

HELP US HELP YOU!

If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to gillian.irwin@case.edu.